"Deregulation of ribosome signalling, synthesis and function during malignant transformation."
Grant number: 400116
A major feature of tumour progression is accelerated cell growth and protein synthesis. Moreover, increased synthesis of ribosomes (the protein synthetic machinery) is associated with malignancy suggesting that it may play a causal role in cancer formation. In support of this, specific inhibitors of both ribosome biogenesis and function are extremely effective in inhibiting the growth of some tumours. This study will examine the mechanisms of deregulation of ribosome biogenesis and function during cancer formation and assess for the first time whether aberrant regulation of ribosome biogenesis and function directly contributes to the initiation and-or progression of cancer.
Related publications (14)
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Nadine Hein, Donald P Cameron, Katherine M Hannan, Nhu-Y N Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch, Jennifer R Devlin, Amee J George, Elaine Sanij, Jaclyn Quin, Gretchen Poortinga, Inge Verbrugge, Adele Baker, Denis Drygin, Simon J Harrison, James D Rozario
Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription
Sandy S Hung, Analia Lesmana, Abigail Peck, Rachel Lee, Elly Tchoubrieva, Katherine M Hannan, Jane Lin, Karen E Sheppard, Katarzyna Jastrzebski, Leonie M Quinn, Lawrence I Rothblum, Richard B Pearson, Ross D Hannan, Elaine Sanij
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
Jaclyn Quin, Keefe T Chan, Jennifer R Devlin, Donald P Cameron, Jeannine Diesch, Carleen Cullinane, Jessica Ahern, Amit Khot, Nadine Hein, Amee J George, Katherine M Hannan, Gretchen Poortinga, Karen E Sheppard, Kum Kum Khanna, Ricky W Johnstone, Denis Drygin, Grant A McArthur, Richard B Pearson, Elaine Sanij, Ross D Hannan
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Jennifer R Devlin, Katherine M Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J George, Jake Shortt, Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O'Brien, Ricky W Johnstone, Grant A McArthur, Ross D Hannan, Richard B Pearson
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E Sheppard, Carleen Cullinane, Katherine M Hannan, Meaghan Wall, Joanna Chan, Frances Barber, Jung Foo, Donald Cameron, Amelia Neilsen, Pui Ng, Jason Ellul, Margarete Kleinschmidt, Kathryn M Kinross, David D Bowtell, James G Christensen, Rodney J Hicks, Ricky W Johnstone, Grant A McArthur, Ross D Hannan, Wayne A Phillips
The mTORC1 Inhibitor Everolimus Prevents and Treats E mu-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L Stanley, Ralph K Lindemann, Michael Bots, Christopher J Chan, Megan J Bywater, Kathryn M Kinross, Megan V Astle, Kelly Waldeck, Katherine M Hannan, Jake Shortt, Mark J Smyth, Scott W Lowe, Ross D Hannan, Richard B Pearson, Ricky W Johnstone, Grant A McArthur
AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer
Joanna C Chan, Katherine M Hannan, Kim Riddell, Yee Ng Pui, Abigail Peck, Rachel S Lee, Sandy Hung, Megan V Astle, Megan Bywater, Meaghan Wall, Gretchen Poortinga, Katarzyna Jastrzebski, Karen E Sheppard, Brian A Hemmings, Michael N Hall, Ricky W Johnstone, Grant A McArthur, Ross D Hannan, Richard B Pearson
Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining In Vivo AKT Isoform Substrate Specificity.
Rachel S Lee, Colin M House, Briony E Cristiano, Ross D Hannan, Richard B Pearson, Katherine M Hannan
The AKT protooncogene mediates many cellular processes involved in normal development and disease states such as cancer. The three..